section name header

Introduction

VA Class:CN302

AHFS Class:

Generic Name(s):

Associated Monographs

Flurazepam hydrochloride is a benzodiazepine.

Uses

Flurazepam shares the actions of other benzodiazepines and is used as a hypnotic agent in the short-term treatment of insomnia for periods up to 4 weeks in duration. Prolonged use of hypnotics is usually not indicated and should be undertaken only upon further evaluation of the patient. The possibility that insomnia may be a symptom of an underlying condition for which there may be a more specific treatment should be considered.

Dosage and Administration

[Section Outline]

Administration !!navigator!!

Flurazepam hydrochloride is administered orally at bedtime.

Dosage !!navigator!!

Dosage of flurazepam hydrochloride must be individualized, and the smallest effective dosage should be used (especially in geriatric or debilitated patients or in those with liver disease or low serum albumin). Prolonged administration of flurazepam should be avoided.

The usual adult dose of flurazepam hydrochloride is 30 mg; however, 15 mg may be adequate in some patients. In geriatric or debilitated patients, an initial dose of 15 mg should be used. In patients who have received prolonged (e.g., for several months) flurazepam hydrochloride therapy, abrupt discontinuance of the drug should be avoided since manifestations of withdrawal can be precipitated; if the drug is to be discontinued in such patients, it is recommended that dosage be gradually tapered.

Cautions

[Section Outline]

Precautions !!navigator!!

A boxed warning has been included in the prescribing information for all benzodiazepines describing the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions associated with all drugs in this class.900 Abuse and misuse can result in overdose or death, especially when benzodiazepines are combined with other medicines, such as opioid pain relievers, alcohol, or illicit drugs.900 Frequent follow-up with patients receiving benzodiazepines is important.900 Reassess patients regularly to manage their medical conditions and any withdrawal symptoms.900 Clinicians should assess a patient's risk of abuse, misuse, and addiction. 900 Standardized screening tools are available ([Web]).900 To reduce the risk of acute withdrawal reactions, use a gradual dose taper when reducing the dosage or discontinuing benzodiazepines.900 Take precautions when benzodiazepines are used in combination with opioid medications.900

Flurazepam shares the toxic potentials of the benzodiazepines, and the usual precautions of benzodiazepine administration should be observed. (See Cautions in the Benzodiazepines General Statement 28:24.08.)

Pediatric Precautions !!navigator!!

Safety and efficacy of flurazepam in children younger than 15 years of age have not been established.

Other Information

[Section Outline]

Chemistry and Stability

Chemistry !!navigator!!

Flurazepam hydrochloride is a benzodiazepine. Flurazepam occurs as an off-white to yellow, crystalline powder which may have a slight odor. The drug is freely soluble in water and in alcohol and has pKa values of 1.9 and 8.16.

Stability !!navigator!!

Commercially available flurazepam hydrochloride capsules should be stored in tight, light-resistant containers at a temperature less than 40°C, preferably at 15-30°C.

Additional Information

For further information on chemistry, pharmacology, pharmacokinetics, uses, cautions, chronic toxicity, acute toxicity, drug interactions, laboratory test interferences, and dosage and administration of flurazepam, see the Benzodiazepines General Statement 28:24.08.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Flurazepam hydrochloride is subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.

Flurazepam Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

15 mg*

Flurazepam Hydrochloride Capsules (C-IV)

30 mg*

Flurazepam Hydrochloride Capsules (C-IV)

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Copyright

AHFS® Drug Information. © Copyright, 1959-2024, Selected Revisions September 26, 2022. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, MD 20814.

References

Only references cited for selected revisions after 1984 are available electronically.

200. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger; 1985:276-7, 393-4.

207. Pharmacia & Upjohn. Halcion® (triazolam) tablets prescribing information (dated 1993 Jul). In: Physicians' desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2093-5.

215. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: Current status of benzodiazepines (first of two parts). N Engl J Med . 1983; 309:354-8. [PubMed 6135156]

216. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: Current status of benzodiazepines (second of two parts). N Engl J Med . 1983; 309:410-6. [PubMed 6135990]

217. Anon. Choice of benzodiazepines. Med Lett Drugs Ther . 1988; 30:26-8. [PubMed 2893246]

218. National Institutes of Health. Drugs and insomnia: the use of medications to promote sleep. Consensus Development Conference. JAMA . 1984; 251:2410-4. [PubMed 6142971]

219. Kales A, Soldatos CR, Kales JD. Sleep disorders: insomnia, sleepwalking, night terrors, nightmares, and enuresis. Ann Intern Med . 1987; 106:582-92. [PubMed 3548525]

221. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA . 1989; 262:3303-7. [PubMed 2573741]

222. Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med . 1987; 316:363-9. [PubMed 2880292]

224. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med . 1988; 148:2441-4. [PubMed 2903726]

235. Elliott WJ. You don't have to be a neuroscientist to forget everything with triazolam—but it helps. JAMA . 1988; 259:350-1. [PubMed 3336151]

245. Kales A, Kales JD. Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects. J Clin Psychopharmacol . 1983; 3:140-50. [PubMed 6132933]

252. Murphy P, Hindmarch I, Hyland CM. Aspects of short-term use of two benzodiazepine hypnotics in the elderly. Age Ageing . 1982; 11:222-8. [PubMed 6129788]

253. Carskadon MA, Seidel WF, Greenblatt DJ et al. Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep . 1982; 5:361-71. [PubMed 6131526]

254. Ogura C, Nakazawa K, Majima K et al. Residual effects of hypnotics: triazolam, flurazepam, and nitrazepam. Psychopharmacology (Berl) . 1980; 68:61-5. [PubMed 6104840]

255. Bixler EO, Kales A, Soldatos CR et al. Effectiveness of temazepam with short-, intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol . 1978; 18:110-8. [PubMed 342551]

256. Linnoila M, Viukari M, Lamminsivu U et al. Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleep aids in psychogeriatric inpatients. Int Pharmacopsychiatry . 1980; 15:129-35. [PubMed 6108299]

257. Kroboth PD, Smith RB, Van Thiel DH et al. Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. J Clin Pharmacol . 1987; 27:255-60.

258. Morgan K, Oswald I. Anxiety caused by a short-life hypnotic. BMJ . 1982; 284:942. [PubMedCentral][PubMed 6121606]

259. Larson EB, Kukull WA, Buchner D et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Inter Med . 1987; 107:169-73.

262. Bixler EO, Kales A, Brubaker BH et al. Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system. Pharmacology . 1987; 35:286-300. [PubMed 2892212]

264. Juhl RP, Daugherty VM, Kroboth PD. Incidence of next-day anterograde amnesia caused by flurazepam hydrochloride and triazolam. Clin Pharm . 1984; 3:622-5. [PubMed 6150782]

267. Kales A, Bixler EO, Vela-Bueno A et al. Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther . 1986; 40:378-86. [PubMed 3530586]

269. Patterson JF. Triazolam syndrome in the elderly. South Med J . 1987; 80:1425-6. [PubMed 3686146]

270. Huff JS, Plunkett HG. Anterograde amnesia following triazolam use in two emergency physicians. J Emerg Med . 1989; 7:153-5. [PubMed 2661672]

276. Ewing JA. You don't have to be a neuroscientist to forget everything with triazolam—but it helps. JAMA . 1988; 259:350. [PubMed 3336151]

279. Morris HH, Estes ML. You don't have to be a neuroscientist to forget everything with triazolam—but it helps. JAMA . 1988; 259:351-2.

280. Cohen M. You don't have to be a neuroscientist to forget everything with triazolam—but it helps. JAMA . 1988; 259:352.

284. Leary WE. F.D.A. asks stronger label on sleep pill under scrutiny. NY Times . 1989; 138(Sep 22):6.

285. Anon. Triazolam (Halcion): psychological disturbances. Drug Ther Bull . 1979; 17:76. [PubMed 43246]

286. van der Kroef C. Reactions to triazolam. Lancet . 1979; 2:526. [PubMed 90240]

287. Oswald I. Triazolam syndrome 10 years on. Lancet . 1989; 2:451-2. [PubMed 2569633]

297. Jerram T. Hypnotics and sedatives. In: Dukes MNG, ed. Meyler's side effects of drugs. 10th ed. New York: Elsevier; 1984:81-108.

298. Jerram T. Hypnotics and sedatives. In: Dukes MNG, ed. Side effects of drugs. Annual 11. New York: Elsevier; 1987:37-43.

311. Kales A, Soldatos CR, Bixler EO et al. Diazepam: effects on sleep and withdrawal phenomena. J Clin Psychopharmacol . 1988; 8:340-6. [PubMed 3183072]

312. Baker Cummins Pharmaceuticals, Inc. Doral® (quazepam) prescribing information. Miami, FL; 1990 May.

313. Ankier SI, Goa KL. Quazepam: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs . 1988; 35:42-62. [PubMed 2894293]

317. Baker Cummins Pharmaceuticals, Inc. Doral® (quazepam) drug reference. Miami, FL; 1989 Jul.

318. Baker Cummins Pharmaceuticals, Inc. Doral® (quazepam) receptor-selective benzodiazepine hypnotic monograph. Miami, FL; 1990 Feb.

319. Baker Cummins Pharmaceuticals, Inc. Product information formulary data for Doral®. Miami, FL; 1989 Jul.

320. Rall TW. Hypnotics and sedatives; ethanol: benzodiazepines and management of insomnia. In: Gilman AG, Rall TW, Nies AS et al. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:346-58,369-70.

321. Kales A, Bixler EO, Soldatos CR et al. Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther . 1982; 32:781-8. [PubMed 7140142]

322. Kales A, Scharf MB, Soldatos CR et al. Quazepam, a new benzodiazepine hypnotic: intermediate-term sleep laboratory evaluation. J Clin Pharmacol . 1980; 20:184-92. [PubMed 6103903]

323. Anon. Quazepam: a new hypnotic. Med Lett Drugs Ther . 1990; 32:39-40. [PubMed 1970112]

325. Hilbert JM, Chung M, Radwanski E et al. Quazepam kinetics in the elderly. Clin Pharmacol Ther . 1984; 36:566-9. [PubMed 6478742]

337. Kales A, Bixler EO, Soldatos CR et al. Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther . 1986; 39:345-52. [PubMed 2868823]

338. Lee A, Lader M. Tolerance and rebound during and after short-term administration of quazepam, triazolam and placebo to healthy human volunteers. Int Clin Psychopharmacol . 1988; 3:31-47. [PubMed 2895786]

344. Kales A, Scharf MB, Bixler EO et al. Dose-response studies of quazepam. Clin Pharmacol Ther . 1981; 30:194-200. [PubMed 6113910]

346. Aden GC, Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry . 1983; 44:454-6. [PubMed 6361006]

348. Kales JD, Kales A, Soldatos CR. Quazepam: sleep laboratory studies of effectiveness and withdrawal. Clin Neuropharmacol . 1985; 8(Suppl 1):S55-62.

353. Mendels J, Stern S. Evaluation of the short-term treatment of insomnia in out-patients with 15 milligrams of quazepam. J Int Med Res . 1983; 11:155-61. [PubMed 6347747]

356. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med . 1989; 321:303-9. [PubMed 2664519]

358. Bloom FE. Neurohumoral transmission and the central nervous system: amino acids. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:256-8.

359. Haefely W. The GABA-benzodiazepine interaction fifteen years later. Neurochem Res . 1990; 15:169-74. [PubMed 2159122]

360. De Feudis FV. Overview—GABAa receptors. Ann NY Acad Sci . 1990; 585:231-40. [PubMed 2162643]

361. Mohler H, Malherbe P, Draguhn A et al. GABAa-receptors: structural requirements and sites of gene expression in mammalian brain. Neurochem Res . 1990; 15:199-207. [PubMed 2159125]

362. Farrant M, Gibbs TT, Farb DH. Molecular and cellular mechanisms of GABA/benzodiazepine-receptor regulation: electrophysiological and biochemical studies. Neurochem Res . 1990; 15:175-91. [PubMed 2159123]

363. Sieghart W. Benzodiazepine receptor subtypes and their possible clinical significance. Psychopharmacol Ser . 1989; 7:131-7. [PubMed 2574448]

364. Knapp RJ, Malatynska E, Yamamura HI. From binding studies to the molecular biology of GABA receptors. Neurochem Res . 1990; 15:105-12. [PubMed 2159117]

365. Williams M. Anxioselective anxiolytics. J Med Chem . 1983; 26:619-28. [PubMed 6132997]

366. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev . 1990; 42:223-86. [PubMed 2217531]

367. Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci . 1989; 238:294-301. [PubMed 2569974]

368. Haefely WE. Benzodiazepines. Int Anesthesiol Clin . 1988; 26:262-72. [PubMed 2461909]

369. Schoch P, Richards JG, Haring P et al. Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature . 1985; 314:168-71. [PubMed 2983231]

370. Haefely W. Endogenous ligands of the benzodiazepine receptor. Pharmacopsychiatry . 1988; 21:43-6. [PubMed 2834760]

372. Pfizer. Xanax® (alprazolam) prescribing information. New York, NY; 2006 Mar.

377. Shader RI, Dreyfuss D, Gerrein JR et al. Sedative effects and impaired learning and recall after single oral doses of lorazepam. Clin Pharmacol Ther . 1986; 39:526-30. [PubMed 3698460]

435. Wyeth Laboratories. Ativan® (lorazepam) injection prescribing information. Philadelphia, PA; 2002 Oct.

470. Bixler EO, Kales A, Manfredi RL et al. Next-day memory impairment with triazolam use. Lancet . 1991; 337:827-31. [PubMed 1672921]

488. Rothchild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psych . 1992; 53:69-79.

491. Schneider PJ, Perry PJ. Triazolam—an “abused drug” by the lay press? DICP Ann Pharmacother . 1990; 24:389-92.

529. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry . 2004; 161(2 Suppl):1-56.

591. Novartis Pharmaceuticals. Clozaril® (clozapine) prescribing information. East Hanover, NJ; 2003 Jan.

592. Grohmann R, Ruther E, Sassim N et al. Adverse effects of clozapine. Psychopharmacology . 1989; 99(Suppl):S101-4. [PubMed 2813662]

593. Sassim N, Grohmann R. Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry . 1988; 21:306-7. [PubMed 2907633]

595. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med . 1991; 324: 746-54. [PubMedCentral][PubMed 1671793]

597. Public Citizen Health Research Group. Citizen's petition to Food and Drug Administration for Dear Doctor Letter and box warning on clozapine regarding risk of respiratory arrest. Washington, DC; 1991 May 29.

598. Friedman LJ, Tabb SE, Worthington JJ et al. Clozapine—a novel antipsychotic agent. N Engl J Med . 1991; 325:518. [PubMed 1852187]

599. Finkel MJ, Schwimmer JL. Clozapine—a novel antipsychotic agent. N Engl J Med . 1991; 325: 518-9.

600. Zenith Goldline Pharmaceuticals. Clozapine tablets prescribing information. Miami, FL; 1999 Feb.

610. Pharmacia & Upjohn Company. Halcion® (triazolam) tablets prescribing information. Kalamazoo, MI; 2003 Jan.

625. Watson Laboratories. Estazolam tablets prescribing information. Corona, CA; 2006 Mar.

629. Food and Drug Administration. Sedative-hypnotic drug products. [March 14, 2007] MedWatch drug labeling changes. Rockville, MD; April 2007. From FDA website. [Web]

700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website. [Web]

701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA . 2013; 309:657-9. [PubMed 23423407]

703. Hughes A. Letter to manufacturers of benzodiazepines: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. [Web]

704. Seymour S. Letter to manufacturers of opioid antitussives: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. [Web]

705. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ . 2015; 350:h2698. [PubMedCentral][PubMed 26063215]

706. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med . 2015; 49:493-501. [PubMed 26143953]

707. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med . 2016; 17:85-98. [PubMed 26333030]

708. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med . 2014; 160:38-47. [PubMed 24217469]

709. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep . 2016; 65:1-49. [PubMed 26987082]

710. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician . 2012; 15(3 Suppl):S67-116.

711. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan. [Web]

712. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun. [Web]

900. US Food and Drug Administration. Drug safety communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class Includes potential for abuse, addiction, and other serious risks. Silver Spring, MD; 2020 Sep 23. From FDA website. [Web]